Koyfin Home > Directory > Health Care > Acceleron Pharma > Net Debt / EBITDA

Acceleron Pharma Net Debt / EBITDA Chart (XLRN)

Acceleron Pharma annual/quarterly Net Debt / EBITDA from 2012 to 2020. Net Debt / EBITDA is a measure of leverage for a company by dividing the Debt less Cash on hand vs. EBITDA.
  • Acceleron Pharma Net Debt / EBITDA for the quarter ending June 06, 2020 was $6m a 62.33% increase of 4m year over year
  • Acceleron Pharma Net Debt / EBITDA for the last 12 months ending June 06, 2020 was $3m a -6.39% decrease of 0m year over year
  • Acceleron Pharma Annual Net Debt / EBITDA for 2019 was $3m a 25.90% increase of 1m from 2018
  • Acceleron Pharma Annual Net Debt / EBITDA for 2018 was $2m a -7.16% decrease of 0m from 2017
  • Acceleron Pharma Annual Net Debt / EBITDA for 2017 was $3m a 16.20% increase of 0m from 2016
Other Ratios Metrics:
  • Acceleron Pharma Total Debt / Capital for the quarter ending December 12, 2013 was $23m a -6,253.89% decrease of -1,413m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
  • Acceleron Pharma Total Debt / Equity for the quarter ending December 12, 2013 was $29m
View Chart On Koyfin

Quarterly XLRN Net Debt / EBITDA Data

06/2020$6m
03/2020$2m
12/2019$4m
09/2019$2m
06/2019$6m
03/2019$3m
12/2018$2m
09/2018$3m
06/2018$2m
03/2018$3m

Annual XLRN Net Debt / EBITDA Data

2019$3m
2018$2m
2017$3m
2016$2m
2015$2m
2014$4m
2013$-12m
2012$1m
2011$-1m